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PREFACE 
 
This study was realized in the Molecular Oncology & Viral Pathology Group of 
the Portuguese Oncology Institute of Porto (IPO Porto) with the support of LETI 
(Laboratorios LETI, Barcelona, Spain) and FOCUS Diagnostics (Focus Diagnostics, 
California, USA). The results obtained in this study will be submitted to publication in near 
future in two different manuscripts: 1) "Prevalence of BKV infection in Hematopoietic Stem 
Cell Transplanted Patients in Portugal"; and 2) "Polyomavirus BKV monitoring 
in Hematopoietic Stem Cell Transplanted Patients". 
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ABSTRACT 
 
Polyomavírus BK (BKV) infection affects 50-100% of patients undergoing allogeneic 
haematopoietic stem cell transplantation (HSCT). Haemorrhagic cystitis (HC) is one of the 
most frequent complications in this type of patients, and it is associated with high morbidity. 
In order to analyse some features of BKV-associated HC in HSCT we have 
developed two independent studies: 1) a retrospective hospital-based study with urine 
samples from 158 patients undergoing allogeneic transplant between 2009 and 2013; and 
2) a prospective study using blood and urine samples from 21 patients submitted to 
allogeneic transplant between November 2014 and March 2015.  
Regarding the retrospective study, we observed that amongst 158 patients, 73.4% 
developed BKV infection. This study revealed that BKV infection was significantly less 
prevalent in patients with >38 years old (p=0.003; OR=0.33; 95%IC 0.15-0.69) and more 
frequent in patients with mismatched or unrelated donors (p=0.006; OR=2.87; 95%IC 1.34-
6.18). The analysis also showed that BKV infection was significantly more frequent in 
patients that developed acute GVHD (p=0.019; OR=2.86; 95%IC 1.16-7.05) and with BKV 
coinfection with CMV (p=0.012; OR=2.51; 95%IC 1.22-5.20). The median time to infection 
was 30 days, the median duration of infection was 52 days with a median of 8.95 log 
copies/mL in urine. Of the patients included in this study, 20.9% developed HC, and of these 
90.9% were BKV-associated HC (p=0.008, OR=4.59, 95%CI 1.32-15.95). This study also 
revealed that patients submitted to myeloablative regimen conditioning have a high risk for 
HC development (p=0.022, OR=2.94, 95%CI 1.13-7.64).  
Regarding the prospective study, we observed that 14.3% of patients developed HC, 
and these patients had a median of 2.71 log copies/mL in blood and of 7.36 log copies/mL 
in urine. This study also showed that viruria ≥4.11 log copies/mL was associated with HC 
development. The correlation between viruria ≥4.11 log copies/mL with clinical variables 
revealed that patients submitted to myeloablative regimen seem to have higher viral load 
than reduced intensity regimen (p=0.055). 
The BKV infection is common in patients undergoing allogeneic haematopoietic 
stem cell transplantation and the development of BKV-associated haemorrhagic cystitis is 
one of the comorbidities that affects these patients. However, there are no specific 
guidelines for the monitoring of BKV infection that should be addressed in the future. 
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RESUMO 
 
A infeção por BKV afeta 50-100% dos pacientes submetidos a transplante alogénico 
de células progenitoras hematopoiéticas. A cistite hemorrágica associada ao BKV é uma 
das complicações mais frequentes neste tipo de pacientes e está associada a uma alta 
morbilidade.  
De modo a estudarmos a infeção por BKV em recetores de transplante alogénico 
de células progenitoras hematopoiéticas e o desenvolvimento de cistite hemorrágica 
realizamos dois estudos independentes:  1) estudo retrospetivo com amostras de urina de 
158 pacientes submetidos a transplante alogénico entre 2009 e 2013; e 2) um estudo 
prospetivo usamos amostras de urina e sangue de 21 pacientes submetidos a transplante 
entre Novembro de 2014 e Março de 2015.  
Relativamente ao estudo retrospetivo, observamos que entre os 158 pacientes, 
73.4% desenvolveram infeção por BKV. Este estudo revelou que a infeção por BKV foi 
menos frequente em pacientes com idades superiores a 38 anos (p=0.003; OR=0.33; 
95%IC 0.15-0.69) e em recetores de dadores não relacionados a infeção é mais prevalente 
(p=0.006; OR=2.87; 95%IC 1.34-6.18). Os resultados também mostraram que a infeção 
pelo BKV é significativamente mais frequente em pacientes com GVHD aguda (p=0.019; 
OR=2.86; 95%IC 1.16-7.05) e mais frequente em doentes com co-infeção pelo CMV 
(p=0.012; OR=2.51; 95%IC 1.22-5.20). O tempo mediano de infeção foi de 30 dias e a 
duração da infeção foi de 52 dias com uma mediana de viruria de 8.95 log copies/mL. Dos 
pacientes incluídos neste estudo, 20.9% desenvolveram HC sendo que 90.9% dos casos 
estava associada à infeção pelo BKV (p=0.008, OR=4.59, 95%CI 1.32-15.95). Este estudo 
também mostrou que os pacientes submetidos a regime de condicionamento mieloablativo 
apresentam maior risco de desenvolver HC (p=0.022, OR=2.94, 95%CI 1.13-7.64).  
Relativamente ao estudo prospetivo, observamos que 14.3% dos pacientes 
desenvolveram HC e, estes pacientes apresentam uma viremia mediana de 2.71 log 
copias/mL e uma viruria de 7.36 log copias/mL. Este estudo mostrou que viruria ≥4.11 log 
copias/mL está associada a o desenvolvimento de cistite hemarragica. A correlação entre 
viruria ≥4.11 log copias/mL com as variáveis clinicas mostrou que os pacientes submetidos 
a regime de condicionamento mieloablativo tendem a ter maior carga viral do que os 
pacientes submetidos a regime de reduzida intensidade (p=0.055). 
A infeção por BKV é frequente em doentes submetidos a transplante alogénico de 
células progenitoras hematopoiéticas e o desenvolvimento de cistite hemorrágica 
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associada à infeção pelo BKV é umas das comorbilidades que afeta estes doentes. 
Contudo, não existem guidelines especificas para a monitorização da infeção por 
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1. Hematopoietic Stem Cell Transplantation 
Hematopoietic stem cell transplantation (HSCT) has been considered a standard 
treatment of hematologic malignancies, congenital or acquired disorders of the 
hematopoietic system, and it has also been applied as a therapeutic option in some solid 
tumours [1]. Recently, HSCT has been indicated as a treatment for autoimmune and 
inherited metabolic disorders [2]. According to World Health Organization (WHO) estimates, 
more than 50 000 HSCT are performed every year worldwide [3].  
 
1.1. General characteristics 
HSCT is a technique used in the treatment of several pathologies, such as, blood 
disorders, immune deficiencies, errors of metabolism and solid tumours, and it consists in 
the infusion of hematopoietic stem cells collected from donors [4, 5]. These stem cells are 
undifferentiated cells, which retain the ability to self-renewal that will give rise to different 
populations of cells depending on the given stimuli [5]. The HSCT intended to replace all or 
part of the hematopoietic system receiver. This process needs ablation of the recipient’s 
bone marrow and tumour cells, which usually entails an use of a high-dose chemotherapy 
and/or total body irradiation. After the conditioning regimen, the hematopoietic stem cells 
are transfused to restore and repopulate the hematopoietic system of the recipient [6]. Bone 
marrow, umbilical cord blood or peripheral blood are frequently used as the source for these 
stem cells [4]. 
Bone marrow aspirates are usually obtained from the posterior iliac crest, and 
because this is a very painful procedure, local and general anaesthesia is always required. 
Even though this procedure is complicated for the donors, sometimes several aspirations 
are necessary for an adequate cell dose. Complications related to bone marrow harvest are 
rare and usually are associated to anaesthetic, infectious, and bleeding problems [7].  
In the bloodstream it is possible to find hematopoietic stem cells at low 
concentrations. Through the administration of growth factors (cytokines G-CSF and GM-
CSF) in donors and patients is possible acquire hematopoietic stem cells through peripheral 
blood. These growth factors increase the concentration of circulating hematopoietic stem 
cells and then can be collected by apheresis [8]. Peripheral blood HSCT grafts, which have 
a greater number of committed progenitors and T cells, have recently been a predominant 
source of HSCT [9].  
Literature has showed that a higher number of hematopoietic stem cells with 
superior proliferative capacity are present in umbilical cord blood [10]. Recently, umbilical 
cord and placenta have been suggested as a good source of hematopoietic stem cells to 
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transplantation procedures since these cells can be cryopreserved in biobanks [9]. The 
properties of cord immune cells allows the umbilical cord blood unit to match with the 
recipient in only 4-6/6 human leukocyte antigen (HLA) alleles [11]. The disadvantages of 
this transplant are related to the higher engraftment failure rate and an increased risk for 
immunosuppression and infection [12].  
HSCT can be classified into two types: autologous and allogeneic. Autologous 
transplantation is usually used as a method of returning the patient’s own stem cells as a 
rescue therapy after a high-dose myeloablative therapy. This transplantation technique is 
commonly used in cases of chemosensitive pathologies. Prior to transplant, the patient 
receives a higher dose of chemotherapy than can normally be tolerated by hematopoietic 
system, in order to eliminate remaining tumour cells. The high-dose chemotherapy is 
followed by subsequent rescue of the host’s bone marrow with previously collected 
autologous hematopoietic stem cells. Immunosuppression is not required after autologous 
transplantation, because the immune system that is reconstituted is from the original host 
[13]. Allogeneic transplantation refers to the use of stem cells from a donor source other 
than the patient. This type of transplant is used to replace a defective host marrow or 
immune system with a normal donor [14].  
A completely matched sibling donor is generally considered the ideal donor. Even 
though related donors are mostly siblings, because they can inherit the same HLA, other 
family members can be considered as donors. When there is no matching donor within the 
family, an unrelated volunteer donor is a valid option [15]. For unrelated donors, a complete 
match or a single mismatch is considered acceptable for most transplantation, although in 
certain circumstances, a greater mismatch is also tolerated [16].  
Transplantation centres have been exploring the use of donors who are only 
haploidentical and are therefore mismatched at all 3 loci. Haploidentical transplantation was 
associated with unacceptably high rates of lethal graft-versus-host disease (GVHD). 
However, the main limitation of haploidentical transplantation is a higher rate of non-
engraftment compared to a matched related donor, and a significant rate of transplant-
related mortality due to infections caused by delayed immune reconstitution [17]. Allogeneic 
transplant is associated with lower relapse rates than the autologous transplant [14]. 
According to the European Registry of Hematopoietic Stem Cell Transplantations, in 2012, 
42% of all HSCT were allogeneic [18]. 
The indications for HSCT vary according to disease categories and are influenced 
by factors such as cytogenetic abnormalities, response to prior therapy, patient 
characteristics, remission vs relapse and others factors [19]. The main diseases treated by 
HSCT autologous or allogeneic are shown in Table 1. 
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Table 1 – Different conditions treated by autologous or allogeneic HSCT 
Autologous HSCT Allogeneic HSCT 
Multiple Myeloma Leukaemias 
Non-Hodgkin Lymphoma Myeloproliferative Disorders 
Hodgkin Disease Myelodysplasic Syndromes 
Acute Myeloid Leukaemia Multiple Myeloma 
Neuroblastoma Non-Hodgkin Lymphoma 
Germ Cell Tumours Hodgkin Disease 
Autoimmune Diseases Aplastic Anaemia 
Amyloidosis Fanconi Anaemia 
 Thalassemia Major 
 Inborn Errors of Metabolism 
 Gaucher Disease 
 Others 
 
Autologous HSCT accounts for 58% of the transplantations done in Europe today; 
47% of the autologous HSCT are performed for multiple myeloma, 30% for non-Hodgkin 
lymphoma, 11% for Hodgkin lymphoma, and 3% for leukaemia. Other less common 
indications for autologous HSCT include autoimmune disease (multiple sclerosis, systemic 
sclerosis and Crohn’s disease) and solid tumours (sarcoma, germinal tumours, and 
neuroblastoma) [23]. Acute myeloid leukaemia and acute lymphoblastic leukaemia account 
50% of the allogeneic HSCT, myelodysplasic syndrome and myeloproliferative neoplasms 
account for 15%, and bone marrow failure syndrome for 6%. Other less common indications 
for allogeneic HSCT include lymphoma, myeloma, and hematologic disorders like aplastic 
anaemia and thalassemia. Indications for HSCT have changed over time [19].  
The conditioning regimen is a critical element in HSCT. The purpose of the 
conditioning regimen is to provide sufficient immunosuppression to prevent graft rejection 
and to eradicate tumours cells. Myeloablative regimens are designed to kill all residual 
cancer cells in autologous or allogeneic HSCT and to cause immunosuppression for 
engraftment in allogeneic HSCT. Total body irradiation and cyclophosphamide/busulfan are 
commonly used as myeloablative therapies [20]. The reduced intensity regimens uses are 
substantially lower doses of chemotherapeutic drugs and radiation that than myeloablative 
regimens. These regimens are immunosuppressive but not myeloablative and rely on the 
graft-versus-tumour effect to kill tumour cells with donor T lymphocytes [21]. 
 
1.2. Risk factors for morbidity and mortality 
The major limitation of allogeneic HSCT remains the high rate of mortality and 
morbidity [22]. High rates of transplant-related mortality (TRM) have been associated with 
infections, GVHD, liver, kidney and pulmonary complications [25]. The reported TRM is 
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highly variable and likely accounted for by the diversity in conditioning regimens, underlying 
disease, stem cell source and comorbidities at time of transplantation [12]. Regarding to 
myeloablative conditioning regimen, TRM can range between 27%-51% in cases of 
unrelated/mismatched donor and 34% in cases of unrelated cord blood transplant [23-
26],while in cases of haploidentical transplantation, TRM can range between 11%-36% [23]. 
In patients undergoing reduced intensity conditioning, TRM can range between 18%-42% 
in cases of haploidentical donor, 11% in cases of unrelated/mismatched donor and, 
between 15%-27% in cases of unrelated cord blood transplantation [27-31].  
Complications can manifest in almost every organ systems and follows a temporal 
sequence that reflects the immunosuppression periods and recovery after transplantation, 
leading to several early and late problems [32]. Early complications occur up to 100 days 
after HSCT and the most common early effects are: nausea; vomiting; pain and mucositis. 
The causes of mucositis are generally associated with conditioning regimen and prophylaxis 
GVHD [33]. Other early complication is hepatic veno-occlusive disease that occurs in 10-
60% of HSCT patients and accounts for 50% of deaths after the procedure [34].  
Transplantation-associated thrombotic microangiopathy is typically characterized by 
microangiopathic haemolytic, anaemia, platelet consumption, and fibrion 
deposition/thrombosis in the microcirculation, most commonly in the kidney [35].  
Late complications occur 100 days after HSCT, and the most frequent are: acute 
GVHD; ocular effects; endocrine effect and congestive heart failure. Transplant patients 
have a high risk of a secondary malignancy, like acute leukaemias, solid tumours or 
myelodysplasic syndrome, and they can develop only several years after a HSCT [36]. Late 
complications are related to the toxicity of the conditioning regimen and/or treatment of the 
disease, the presence of GVHD and immunosuppression status [37].  
The prognosis of patients submitted to allogeneic HSCT is influenced by 
several factors, including type of transplantation, patient’s characteristics, prolonged 
and severe pancytopenia, GVHD, graft failure and infections. 
 
1.2.1. Patient characteristics 
Age of patient, the underlying disease process, and presence of residual disease 
are important prognostic factors [38]. In general, the prognosis is poorer in adults because 
they have high relapse rates of tumour. This relapse rate is also high in patients with residual 
disease [39]. 
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1.2.2. Prolonged and severe pancytopenia 
Pancytopenia is a reduction of all types of blood cells, and in some patients is 
prolonged and severe. Severe and prolonged neutropenia (up to 4 weeks) is common after 
transplantation and requires the use of broad-spectrum antimicrobials until recovery of the 
neutrophils [40]. However it still contributes to a serious risk of infections occurring in up to 
50% of patients after transplantation [40]. Additionally, thrombocytopenia has also been 
considered a risk factor, which can leads to a severe bleeding due to organ damage caused 
by chemotherapy, acute GVHD or infections. In most cases, prevention is accomplished by 
platelet transfusion [41]. 
 
1.2.3. Graft-versus-host disease 
GVHD occurs when immunocompetent T cells and natural killer cells in the donor 
graft recognizes host antigens as foreign targets and mediates a reaction. GVHD occurs 
more frequently in allogeneic HSCT than autologous HSCT. GVHD is classified in acute 
and chronic form and is associated with high mortality and morbidity after HSCT [42]. 
Literature also reports that GVHD severity is inversely related to the relapse risk [42].  
Acute GVHD is one of the most important complications associated to allogeneic 
HSCT and typically occurs within 100 days after transplant [43]. Acute GVHD may occur in 
skin, mucosal surfaces, gut and liver. Risk factors for acute GVHD include HLA-mismatched 
grafts, matched unrelated grafts, and advanced patient age [43].  
The literature describes that approximately 40-80% of long-term survivors may 
develop chronic GVHD. Chronic GVHD develops 2-12 months after HSCT and can affect 
skin, eyes, mouth, liver, fascia, and almost any organ in the body.  The patient’s age is an 
important factor for chronic GVHD development, since its incidence is higher in older 
patients. Other risk factors include mismatched or unrelated donors, second transplant, and 
donor leukocyte infusions. The greatest risk for chronic GVHD is acute GVHD [44].  
 
1.2.4. Graft failure 
Graft failure is associated with increased risk of infection and post-transplant 
mortality [45]. One of the most important risk factors for graft failure is the HLA compatibility. 
The greater the degree of HLA mismatched, the greater the risk of graft rejection. Other risk 
factors for failure include T-cell depletion of the donor graft, infusion of lower number of 
hematopoietic stem cell, reduced intensity regimen, GVHD, use of methotrexate, 
mycophenalote mofetil, antithymocyte globulin and ganciclovir [46]. 
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1.2.5. Infections 
Many factors predispose to the development of infections in transplant patients, such 
as mucous and skin damage caused by conditioning regimen and catheters, neutropenia, 
immunosuppression status, GVHD, type of stem cells used and underlying disease process. 
Infections is reported as the primary cause of death in 17-20% of allogeneic HSCT 
recipients [47, 48]. Specific immune defects are associated with different stages of 
transplantation, or risk periods: pre-transplant period; pre-engraftment period 
(approximately 0-30 days after transplantation); post-engraftment period (approximately 30-
100 days post-transplantation); and late post-transplantation period (≥100 days after 
transplantation) [32]. 
 
1.2.5.1. Pre-transplant period 
Infections during the pre-transplantation period are very heterogeneous and 
the host status and therapy determine risk of infection during this period. At this 
stage, the pre-existing neutropenia promotes infections [49].  
Most infections that occur during this phase are secondary to aerobic gram-
negative bacilli, such as Klebsiella species and Escherichia coli. Local infections 
most commonly involve skin and soft tissue, the oral cavity, or urinary tract (60%), 
whereas sepsis (24%) and pneumonia (10%) occur less commonly. During this 
phase, the severity and mortality rates are low [32]. 
Figure 1 – Some complications and infections after HSCT. Adapted from 
http://www.ufrgs.br/imunovet/molecular_immunology/grafts_HSCT.html. 
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1.2.5.2. Pre-engraftment period 
In the pre-engraftment period (approximately 0-30 days post-transplantation), the 
major risk for acquiring infection is neutropenia and altered barrier defences resulting from 
the HSCT conditioning regimen [50]. The sources of pathogens for infection during this 
period are the patient's skin flora, oral flora, and gastrointestinal tract flora. With the patient’s 
immune system unbalanced, the microorganisms which normally colonize these areas 
become pathogenic [51].  
The predominant infections during this phase are bacterial, occurring in 15%-50% 
of recipients of HSCT [52].  Bacterial pneumonias have an incidence of 12%-15% in the first 
100 days after HSCT and are more common in allogeneic HSCT. Most pulmonary infections 
occurring in this phase are secondary to opportunistic fungal infections (Aspergillus most 
commonly, with Fusarium, Cryptococcus, Candida, and Mucor observed less commonly)  
[53]. Less observed is typhlitis or neutropenic enterocolitis, which tends to occur with severe 
neutropenia. Typhlitis has a mortality rate of 50%-100% [32]. Other microorganism rarely 
described is Nocardia, which has been associated with a pulmonary illness with nodules 
with or without pulmonary infiltrates [54]. 
In patients undergoing allogeneic HSCT, the incidence of fungal infections is about 
10-20% constituting one of the causes of mortality after transplantation [55, 56]. Fungal 
infections are generally caused by two specific pathogens: Candida species 
and Aspergillus species [57]. Candida infections occurs in approximately 11% and 
Aspergillus infections occurs in 4%-20% of HSCT recipients [58, 59]. Numerous other fungi 
have been reported to cause infection in the HSCT patient, including Pseudallescheria 
boydii and Scopulariopsis, Fusarium, Trichosporon, Rhodotorula, Alternaria, Acremonium, 
Pityrosporum, Bipolaris, Curvularia, and Penicillium species [60]. 
During the pre-engraftment phase, about 80% of patients may be infected by Herpes 
Simplex Virus (HSV), and the usual mechanism of appearance is reactivation of prior latent 
infection. Human herpesvirus 6 (HHV-6) infection, which has an incidence that rounds 33% 
to 48%, may also be a cause of undiagnosed fevers during the pre-engraftment period [61]. 
Other virus that can reactivate in these patients is Varicella Zoster virus (VZV), although 
less common (about 13-38%) [32]. 
1.2.5.3. Post-engraftment period 
In the post-engraftment period (approximately 30-100 days after HSCT) bacterial 
infections become less frequent, except in patients with continued central venous line 
access. These patients are at continued risk for central line infections secondary to 
staphylococcal bacteria [62].  
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The most important pathogens during this phase are the herpes virus, especially 
Cytomegalovirus (CMV). CMV infection occurs more commonly in patients undergoing 
allogeneic HSCT with risk factors such as recipient seropositivity, histocompatibility 
differences, older ager, GVHD prophylaxis and conditioning regimen [62]. Of all patients 
who have undergone HSCT and acquire CMV infection, 15%-20% die. CMV pneumonia is 
the major cause of this type mortality, being responsible for 80-90% of the deaths [32].  
Adenoviral infection occurs in 4.9%-20.9% of patients undergoing HSCT and can 
lead to significant morbidity and mortality [63]. The mortality rate in immunocompromised 
patient is 18-60% and depends on patient age, type of HSCT, and adenovirus subtype [64, 
65].  
The respiratory viruses, such as respiratory syncytial virus (RSV), 
influenza, parainfluenza, and the picornaviruses can be found in the post-engraftment 
phase, leading to respiratory disease. In immunocompromised individuals, respiratory 
viruses are associated with a high mortality rate and often have a prolonged course and 
progress to pneumonia [66].   
Haemorrhagic cystitis (HC) is a well-known complication of HSCT and it is known to 
be caused by various etiological agents such as bacteria (eg, Escherichia coli), fungi and 
viruses. The virus associated with HC are adenovirus, influenza A and BK virus (BKV) [67, 
68]. Some studies have reported that HC may be more likely to be associated with BKV 
than adenovirus [67, 68].  
During this period, parasitic infections also tend to occur. Pneumocystis jiroveci 
pneumonia was a major opportunistic infection leading to significant morbidity and 
mortality. Toxoplasmosis has also been described in a small number of patients during this 
phase of transplantation [32].  
 
1.2.5.4. Late post-transplantation period 
During late post-transplantation period (≥100 days after HSCT) infection is generally 
localized to the skin, the upper respiratory tract, and the lungs [50]. Viral infections, 
especially secondary to VZV, are responsible for more than 40% of infections during this 
phase, bacteria are responsible for approximately 33%, and fungi cause approximately 20% 
[32].  
At this stage there is an increased susceptibility to encapsulated bacteria 
(eg, Streptococcus pneumoniae, Neisseria meningitidis). Systemic fungemia is not 
commonly observed at this stage, but oropharyngeal candidiasis, Aspergillus 
sinopulmonary and disseminated infections may occur [32].  
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2. Polyomavirus BK 
In HSCT patients patients, viral infections are one of the causes of morbidity and 
mortality contributing to tissue damage, immunosuppression and also graft failure [69][70]. 
BKV was isolated in 1971 by Gardner and his co-workers, from urine and urethral 
epithelial cells of a patient undergoing kidney transplantation, with chronic pyelonephritis 
and advanced renal failure. As the virus was not yet known, Gardner decided name it from 
the initials of the patient [71]. The BKV belongs to Polyomaviridae family, other members 
are JC-virus (JCV) and Simian-virus 40 (SV40). BKV has a homology of 70-75% with SV40 
and JCV [72].  
 
2.1. Structure and genome 
BKV is a small virus with 40-45 nm in diameter, non-enveloped double chain DNA 
comprising 5000 base pairs. The viral capsid is composed of structural viral protein (VP) 1, 
2 and 3, forming an icosahedral capsid [73]. The functional viral genome is divided into: non 
coding control region (NCCR); early coding region, which encodes major tumour antigen 
(T-Ag), small tumour antigen (t-ag) and truncated tumour antigen (trunk-T-Ag); and late 
coding region, which encode viral capsid proteins and agnoprotein [74]. 
  
2.1.1. Noncoding control region  
The NCCR is located between the late and early regions, contains binding sites of 
T-Ag and the DNA replication origin [75]. The sequence of NCCR functions as a promoter 
and regulatory region or has several binding sites for the transcription factors that modulate 
viral transcription [76]. 
 
2.1.2. Early coding region 
The early region encodes two proteins involved in the transformation process, T-ag 
and t-ag [77]. The T-Ag protein has the ability to bind to DNA and other cellular proteins 
such as the retinoblastoma family, DNA polymerase, and p53 [78-80]. T-Ag has helicase 
and ATPase activity, which is important for viral replication [81]. Thus, the functions of T-Ag 
are regulate messenger RNA (mRNA) production, initiate viral replication and activate the 
latent viral genes [65]. It is also responsible for the establishment and maintenance of cell 
transformation, allowing cellular immortalization [82]. For the replication of viral DNA, the 
host cells need to be in the S phase of the cell cycle [82]. 
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Moreover, the t-ag role in BKV life cycle is not well-understood [83]. The majority of 
the studies on this protein function were performed on SV40. These studies demonstrated 
that t-ag is able of binding to protein phosphatase 2A in order to inhibit its function and 
stimulating cell growth [84]. The t-ag is also important for efficient viral replication and, 
together with the T-Ag may have an important role in cellular transformation [85].  
 
2.1.3. Late coding region 
The late region encodes for the agnoprotein and three capsid proteins (VP1, VP2 
and VP3) containing DNA-binding motifs [86].  
The VP1 is the major structural protein and has the ability to bind to cellular 
receptors, and is crucial for entrance into the host cell. This VP1 function is correlated with 
its structural distribution, where VP1 looping structures are projected outwards, from the β-
sheet, providing antigenic structures, receptor binding sites or domains responsible for 
hemagglutination [87, 88]. The VP2 and VP3 are proteins that forms internal capsid by 
binding to a central groove in the inside part of VP1. The sequence of the carboxyl terminal 
region of VP2 and VP3 corresponds to an interactive domain of VP1, a DNA binding site 
and a nuclear localization signal. The VP2 and VP3 proteins form complexes with VP1 
through its carboxyl terminal, allowing the formation of virus [89, 90]. 
The agnoprotein facilitates the transport of VP1 during lytic infection, allowing it to 
move from the cytoplasm to the perinuclear space [91]. This protein regulates viral 
transcription, translation and virus formation/maturation. Furthermore, it contributes for the 
suppression of cell growth, by binding directly to the p53, and for the suppression of cell 
proliferation due to dysregulation of the cell cycle [92]. The agnoprotein also interacts with 
T-Ag, influencing the replication and transcription of the viral DNA, and inhibits the repair of 
cellular DNA [93, 94]. 
 
 
2.2. Infection and replicating cycle 
 
2.2.1. Primary infection and reactivation 
The primary BKV infection occurs during childhood, through respiratory or 
gastrointestinal track, being asymptomatic [95]. After infection, the virus may be in 
a state of latency in peripheral blood, brain, B lymphocytes and uroepithelial cells, 
being the kidneys the most important latent site. After a latent state which may be 
                                                                                                                              Nádia Neto | MSc Oncology 
 
  Polyomavirus BK viruria and viremia in Hematopoietic Stem Cell Transplantation|13 
 
several years, the virus can be reactivated [96, 97]. The pathogenesis of BKV infection has 
the following sequence: viral entry into the host; multiplying in the entrance location; viremia 
and displacement of the virus to the target organ; and BKV replication in target organs [75]. 
The duration or intensity of viral replication varies with the degree of immunosuppression of 
the host [83].  
In an immunosuppression state, like pregnancy, oncologic disease, HIV infection, 
diabetes or transplant organs/HSCT, the reactivation of the virus is associated with the 
occurrence of disease [97-99]. In patients undergoing allogeneic HSCT, the reactivation of 
BKV is influenced by the effects of the immunosuppressive agents, anti-viral immune 
response, viral load, genetic characteristics of the virus, and histocompatibility of the donor 
and recipient [98, 100]. 
  
2.2.2. Replication cycle 
The replication cycle of BKV is initiated by binding to N-linked glycoproteins with 
α2,3-linked sialic acids and gangliosides GD1b and GT1b which are receptors for BKV 
[101]. BKV is internalized via caveolae-mediated endocytosis, and it is transported towards 
the endoplasmatic reticulum via microtubules [74]. Disassembly of the outer capsid is 
essential for the exposure of VP2 and VP3, which mediate entry into the nucleus via 
importins [102]. Once inside the nucleus, the early BKV genes are expressed. T-Ag 
prepares the infected cell for viral replication, by binding to the origin of replication and 
locally unwinding the double-stranded DNA. Once the BKV genome does not encode DNA 
polymerase, it recruits the replication machinery of the host cell [74]. After DNA replication, 
the latent genes are expressed and there is virion accumulation in the nucleus, resulting in 
disruption of the cell membrane, releasing them into the extracellular space [74].  
Literature reported that BKV can exist in latent phase in various organs, and can 
remain within cell in a nonreplicating or minimally replicating form  [103]. Within the cell, the 
latent viral genome may either remain episomal or it may be integrated in the host cell 
genome. In either state, few viral genes are transcribed, thereby keeping the virus out of 
reach of the immune system [104]. The kidney is the most common reported site of latent 
infection, followed by brain and leukocytes [105-107]. A more recent study has been 
suggested that BKV is only present in blood during the reactivation period and not during 
latency [108]. There are limited data that suggest the involvement of other sites and tissues, 
including the pituitary gland, tonsils and nasopharynx, genital tissue and sperm, lung, liver, 
and bone [107, 109-113].  
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Figure 2 –Schematic representation of BKV infection (Fishman, 2002).  
 
2.3. Transmission and epidemiology 
BKV infection is anthroponosis and endemic, affecting both genders, with ubiquitous 
and non-seasonal distributions, and is not related to the socio-economic status of 
populations. There are several modes for transmission, mostly through direct inter-human 
contamination: respiratory; uro-oral and feco-oral borne; blood-borne; and sexual (sperm 
carriage) [72]. The primary BKV infection occurs during childhood or in early adulthood, with 
a seroprevalency of about 80%. Although BKV infection present a prevalence of 80% does 
not indicate an active infection [115]. Reactivation and asymptomatic urinary shedding is 
described in nearly 10% of healthy individuals, worldwide. In the immunocompromised 
population, it has been shown the presence of high viral load of BKV in the urine, even in 
asymptomatic individuals [116].  
BKV is classified into four subtypes (I-IV) using serological and genotyping methods 
[117]. The regional distribution of the BKV subtypes has been established in several studies. 
It has been hypothesised that BKV has co-migrated with human populations in general 
[118]. Subtype I is widespread throughout the world, Subtype IV shows a geographical 
distribution biased for East Asia (with exception Japan), and Subtypes II and III are rarely 
detected worldwide [119]. 
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2.4. Associated diseases 
Different diseases have been linked to BKV infection and the most frequent are: 
polyomavirus-associated nephropathy, which affects kidney transplant patients; and 
polyomavirus-associated HC, which affects patients undergoing HSCT. Other less frequent 
diseases have also been associated with BKV: ureteric stenosis, encephalitis and 
meningoencephalitis, pneumonia, vasculopathy and bladder cancer [86, 120-122]. 
 
2.4.1. Polyomavirus-associated nephropathy 
The first report describing disease resembling BKV-associated nephropathy in 
kidney transplant patients, came as early as 1978 [123]. BKV-associated nephropathy 
affects between 1 and 10% of kidney transplant patients during the first two years post-
transplantation [100]. The pathogenesis is associated with the high level BKV replication in 
renal-tubular epithelial cells of the transplanted kidney, which leads to cytopathic loss and 
thus denudation of the epithelial monolayer in the allograft tubulus. As a consequence of 
this, virus leak into the tissue and bloodstream and inflammatory cells infiltrate in the 
interstitium leading to tubular atrophy and interstitial fibrosis [124]. 
 
2.4.2. Ureteric stenosis 
There have been several reports on BKV-associated ureteric stenosis, usually in 
kidney transplant patients, but also in allogeneic HSCT patients [120, 125]. The 
pathogenesis of ureteric stenosis is still not completely resolved [126].  
  
 
2.4.3. Central nervous system involvement 
The literature describes the involvement of BKV in central nervous system diseases 
in immunocompromised patients [112, 127, 128]. The first described case was a man with 
type 2 haemophilia and AIDS, who developed subacute meningoencephalitis and 
consequently died. It was found both BKV DNA and proteins in the central nervous system, 
kidneys and lungs suggesting a widespread disease [112]. 
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2.4.4. Rare diseases 
There has been reported some isolated cases in which BKV might be involved. An 
example is a case of systemic vasculopathy with capillary leakage and multi organ failure 
that has been reported in a renal transplant patient [129]. Unlike other common virus, where 
pneumonia is a frequent associated comorbidity of the infection, in the BKV infection such 
is not described. However, in an autopsy of a HIV patient, it was found that the patient had 
also BKV pneumonia [112]. 
Furthermore, in some cases of bladder cancer, both the primary tumour and the 
metastasis have been found to be BKV positive [86]. In 2012, BKV and JCV were classified 
as possibly carcinogenic to humans by WHO [130]. BKV has been associated with others 
human neoplasms, like prostate carcinoma, brain tumours, pancreatic islets tumours, 
Kaposi sarcoma, Ewing sarcoma and osteogenic sarcoma [107, 131].  
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3. Haemorrhagic Cystitis 
 
3.1. Characteristics and pathophysiology 
HC is characterized by a haemorrhagic inflammation, which occurs in the mucosa 
of the urinary tract. Among other complications, HC deteriorates the quality of life, since it 
extends hospitalization time [132]. 
Comparing patients who underwent transplantation that have developed HC with 
patients who did not develop HC, it was found that the first had an overall and event free 
survival smaller in comparison with other [133]. The reported incidence of HC after 
transplantation may vary between 10% and 70% [134]. Several risk factors for the 
development of HC in HSCT have been reported [135] – Table 2. 
Most cases of HC in cancer patients are due to: the accumulation of 
chemotherapeutic agents metabolites; bladder damage from exposure to radiation; and 
viral, bacterial, fungal or parasitic infections in immunocompromised individuals. In some 
forms of cancer, the primary tumour can also be a factor HC [136]. 
In cases of HC caused by chemotherapeutic agents, the most common agent is 
cyclophosphamide [137]. The incidence of HC in patients receiving high doses of this 
therapy is quite high, surrounding 20% [138]. This type of HC is associated with high 
morbidity and can result in vesicular haemorrhage, with mortality rates up to 75% [139]. 
 
Table 2 – Risk factors for HC following HSCT 
Adenovirus antibody at time of transplant 
Conditioning Regimen 
CMV infection 
Use of ATG and corticosteroids 
Male gender 
History of GVHD 
BKV infection 
Unrelated donor 
Haploidentical or cord blood donor 
 
Approximately 20% of patients receiving pelvic radiation experience some sort of 
bladder toxicity [140]. Unlike the toxicity caused by cyclophosphamide, haematuria may 
occur months or even years after therapy, and may appear as microscopic haematuria or 
life-threatening HC [141, 142]. 
HC with viral infection was predominantly observed in the HSCT population. HC 
induced by virus was first observed in the mid-1970s, when an outbreak of type II 
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adenovirus was associated with urinary symptoms and gross haematuria in 
immunocompetent children [143, 144]. Today, it is known that BKV also has an 
role in the development of HC in the HSCT population [145]. BKV is common in the 
general population and persists in a latent form in the kidney after a primary infection. 
A subsequent immunosuppression will activate the latent virus resulting in viruria 
[146]. 
 
3.2. BKV-associated HC in allogeneic HSCT recipients 
Leung and his co-workers suggested a disease model for BKV in which 
chemotherapy with cyclophosphamide or radiation caused direct damage to epithelial cells 
of the bladder, and that will subsequently act as a "trigger" for BKV out of lag phase to start 
replication [147]. 
The host is unable to have an immune response to BKV replication, since due to 
HSCT their immune responses are weak. The BKV replication can be detected in the urine, 
but at this stage the patients are asymptomatic. As the new host's immune system recovers, 
the recognition of BKV replication and the attempt to control it, leads to an inflammatory 
response and consequent damage to uroepithelial cells. The BKV disease can manifest 
through various signs and symptoms [148]. Further publications suggest that this model 
must be expanded to include factors that alter the host immune response over time, as well 
as the factors involved in host-pathogen interaction [149]. 
There is an increased incidence of BKV reactivation in HSCT patients with HLA-
mismatched donors or cord blood from unrelated donors than other HSCT patients [150]. 
These observations suggest a crucial role of the major histocompatibility complex (MHC) -
based viral recognition [150]. 
On the other hand, the host immune response may not be the only factor in the 
development of BKV disease in HSCT patients. Patients who undergo unrelated cord blood 
transplantation can develop pre-engraftment BKV disease without having been conditioning 
with cyclophosphamide or radiotherapy. Patients can also develop BKV disease late in the 
transplantation course, during treatment of acute or chronic GVHD. These circumstances 
suggest that loss of immune control, without inciting cytotoxic injury, may lead to BKV 
reactivation and disease. These facts also suggest that clinical disease may be a result of 
direct viral cytotoxic effects in the setting of intense immunosuppression and not solely 
caused by immune reconstitution. However, if the host gains immune control of the virus, 
several outcomes may ensue, including; resolution of BKV viruria without clinical disease; 
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resolution of genitourinary signs and symptoms without sequelae; or post-BKV disease 
manifested by bladder and urinary tract scarring [151]. 
BKV-associated HC  arises from complementing determinants in the host, the target 
organ and in the virus in the setting of immunosuppression [152]. Evidence of prior infection 
in the host and presence of anti-BKV IgG prior to treatment has been associated with BKV 
viruria, which occurs secondary to reactivation of virus from a latent state [153]. Acute 
GVHD, the conditioning regimen, specific BKV subtypes and BKV viral load in urine have 
been identified as risk factors for BKV virus-associated HC [154] - Table 3. The alloimmune 
reaction, characteristics of GVHD, or its treatment is suspected to play a significant role in 
the pathogenesis of BKV-associated HC. Studies suggested an immune reconstitution 
pattern of disease, whereby the disease manifestations are most severe when the immune 
system is reconstituting and viral antigens in the bladder wall are recognized by emerging, 
functioning lymphocytes [155].   
 
Table 3 – Potential risk factors for BKV-associated HC (Leung, 2002). 
Presence of pre-transplant BKV IgG antibody titter 
Type of conditioning regimen 
Allogeneic hematopoietic stem cell transplantation 
Type of donor 
Acute GVHD 
High peak BKV urine viral load or greater than 3 log increase in viral load 
 
3.2.1. Diagnosis 
HC is characterized by bladder inflammation associated with haematuria. Patients with 
this condition usually present with urgency, frequency, dysuria, and, in some cases, 
abdominal discomfort. Symptoms include suprapubic discomfort, urinary frequency, and 
inability to empty the bladder due to the clots [156]. Moreover, patients have varying levels 
of haematuria, and as a result there is grading system to help assess severity as well as 
diagnosis [146] – Table 4. 
The diagnosis of HC is considered when haematuria is detected in the urine test in the 
post-transplant or post-engraftment period. Since the late start of HC that occurs post-
engraftment is associated with BKV, the presence of the virus is searched. Cytologic 
examination of urine can detect characteristic polyomavirus-infected cells, decoy cells, with 
an enlarged nuclei containing a single large basophilic intranuclear inclusion [157]. The 
limitations of cytology include that these decoy cells can be confused with malignant cells 
and that infection caused by JCV or adenovirus can result in similar cytopathology [147]. 
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Table 4 – Haemorrhagic cystitis grade (Bedi, 1995). 
Grade Definition 
I Microscopic haematuria 
II Macroscopic haematuria 
III Macroscopic haematuria with clots 
IV 
Gross haematuria with clots causing urinary obstruction and renal failure 
requiring intervention 
 
Therefore, the modality of choice for detecting BKV in urine is the PCR for detection 
of viral DNA. However, detection of BKV DNA by PCR does not have high disease 
specificity because HSCT patients without HC can also excrete BKV [135, 156]. Other 
features of reactivated viral replication can be utilized to link BKV replication to the cause 
of HC: detection of viruria prior to the onset of haematuria, high viral loads (>108copies/mL 
or ≥3 log increase from baseline) and the presence of plasma viremia >104copies/mL [158].  
Detection of decoy cells and BKV DNA in urine does not confirm BKV 
disease, and often represents asymptomatic reactivation. The sensitivity of alternate 
diagnostic tests to confirm BKV disease, such as the detection of BKV in the urine 
or blood, have not been studied in post-HSCT patients [75]. 
 
3.2.2. Treatment 
The therapeutic approach to HC its variable because it depends on the several 
factors. In general, treatment is designed to control bleeding. The current standard of care 
for HC related to chemotherapy or BKV infection is symptomatic and includes analgesia, 
hyperhydration, forced diuresis and continuous bladder irrigation to prevent clot formation 
and renal obstruction. Minor cases of BKV associated HC usually resolve spontaneously 
over a 2-week period with supportive care. With significant bleeding, severe urinary tract 
obstruction may also occur because of clot formation. In these cases, cystoscopy and 
cauterization must be performed to preserve renal function. When conservative measures 
fail a surgical intervention, cystectomy, must be considered [159]. Instillation of agents, such 
as alum, formalin and prostaglandin E1, into the bladder is used; however, the efficacy of 
these approaches remains controversial due to the absence of controlled studies and the 
possibility of the long-term morbidity [160].  
Even though several antiviral drugs have been tested for the treatment for BKV, until 
now none has been licensed.  One of these drugs is cidofovir, which is an acyclic nucleoside 
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analog with antipolyomavirus activity that has demonstrated some activity against BKV 
[161]. The mechanism by which cidofovir inhibits BKV replication is not clear. Investigators 
speculate that cidofovir may inhibit a functional domain of the BKV T-Ag that possesses 
DNA polymerase activity, or since this drug is a nucleoside analog, the antiviral effect may 
be the result on inhibition of viral DNA synthesis [162, 163]. Another drug, leflunomide 
inhibits protein kinase activity and pyrimidine synthesis. Till date, reports of treatment of 
BKV associated-HC with leflunomide have not been described, however, given this agent’s 
antiviral activity against BKV, leflunomide should be considered as a potential agent to treat 
BKV associated-HC [155]. Some studies demonstrated that fluoroquinolone antibiotics, 
nalidixic acid and oxolinic acid, can inhibit BKV replication in vitro [164]. These drugs inhibit 
bacterial replication by inhibiting the activity of type II topoisomerases, including gyrase and 
topoisomerase IV. Researchers speculate that these DNA gyrase inhibitors may inhibit BKV 
replication by inhibiting the helicase activity of the BKV T-Ag [164]. 
For radiation induced HC, hyperbaric oxygen is frequently used, and it has also been 
reported to be benefit for patients with BKV associated-HC. Apparently the hyperbaric 
oxygen stimulates mucosal repair in the urinary bladder [165]. 
Brennan and collaborators have shown in renal transplant patients that reduction of 
immunosuppression resulted in resolution of BKV viremia, absence of BKV-associated 
nephropathy and low risk for acute rejection or graft loss [166]. Furthermore, new biological 
strategies for tissue reparation such as mesenchymal stem cells may be implicated in the 
treatment of HSCT-associated HC [167]  
 
 
3.2.3. Monitoring 
A number of viruses that play a particularly important role after allogeneic HSCT are 
included in regular diagnostic screening programs (e.g., CMV, Adenovirus), while testing 
for other viruses is performed only upon particular suspicion [168]. Literature suggests that 
a BKV viral load in urine >108 copies/mL is an important risk factor for HC, and quantitative 
PCR monitoring may therefore be a helpful tool for treatment strategies [168]. However, 
there are no guidelines for BKV monitoring because the clinical impact of this virus remains 
unclear [168].  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. AIMS OF STUDY 
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BKV has been frequently found in blood and urine specimens among patients 
underwent to allogeneic HSCT. Although BKV is a well-known causative agent for 
development of HC, there are still no well-defined guidelines for detection and monitoring 
this infection. Thus, contributing for the knowledge to development of guidelines, the main 
objective of this study was to characterize BKV infection in patients submitted to allogeneic 
HSCT. 
To optimize the potential of this study, specific objectives were defined:  
 1. Determine the prevalence of BKV infection in allogeneic HSCT patients 
 2. Characterize BKV infection and correlate with potential risk factors 
 3. Compare viral load in blood and urine samples 
 4. Set up a correlation between viremia and viruria with HC development. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. MATERIAL AND METHODS 
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This dissertation consists in two independent studies: a retrospective hospital-based 
study and a prospective hospital-based study. In both studies, the study population consists 
in patients undergoing allogeneic HSCT in Transplantation Service Bone Marrow of IPO-
Porto FG EPE. This study did not interfere with the routine procedures. Clinicopathological 
data was collected from individual clinical records and inserted on a database with unique 
codification. All procedures were approved by the ethical committee of IPO Porto (CES IPO 
75/2015).  
 
1. Retrospective Study (Study 1) 
 
1.1.  Type of study and population 
A retrospective study was performed including a total of 158 patients submitted to 
allogeneic HSCT between 2009 and 2013 which were monitored for BKV infection in 
Virology Service of the IPO Porto. We selected patients who had at least two monitoring 
during follow-up, and the samples was collected depending on the clinical requests. 
 
1.2. Sample processing and nucleic acids extraction 
Urine samples selected from allogeneic HSCT patients were processed for nucleic 
acid extraction, without centrifugation or cell lysis, with MagNA Pure Compact Nucleic Acid 
Isolation Kit I (Roche, Mannheim, Germany). Nucleic acids extraction was performed in 200 
µL of sample. 
 
1.3. BKV DNA quantification 
BKV infection monitoring was performed on urine samples by real time PCR using 
Q-BKV Real Time kit (ELITech Group®, Puteaux, France) according to manufacturer 
instructions. This kit amplifies a fragment from the T-Ag gene of BKV and a fragment from 
beta globulin gene as extraction control. The reactions were performed in the 7300 real 
Time PCR System (Applied Biosystems, California, USA). Amplification signals obtained 
from the samples are compared to a calibration curve, developed with the BKV Standards 
(ELITech Group®, Puteaux, France), and quantified.  
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2. Prospective Study (Study 2) 
 
2.1. Type of study and population 
A prospective study was performed including 21 patients submitted to 
allogeneic HSCT between November 2014 and March 2015 at IPO Porto. Patients 
were selected if had a urine and a blood sample on the same day during the post-
transplant follow-up period. We performed the BKV detection on the 30th, 60th, 90th 
and 120th days after transplant. 
 
2.2. Sample processing and nucleic acids extraction 
Blood and urine samples were processed for nucleic acid extraction, without 
centrifugation or cell lysis, with High Pure Viral Nucleic Acid Kit (Roche, Mannheim, 
Germany). Nucleic acid extraction was performed in 200 µL of sample following the 
manufacturer’s instructions. 
 
2.3. BKV DNA quantification 
The test system Simplexa BKV kit (Focus Diagnostics, California, USA) 
intended for in vitro detection and quantification of BKV nucleic acids in blood and 
urine samples using 3M Integrated Cycler (Focus Diagnostics, California, USA). The 
test consists in amplification and detection by real time PCR with a bifunctional 
fluorescent primer-probe, labeled with fluorochrome FAM, which binds to a well 
conserved region of the VP2 gene. The extraction process is monitored by an 
internal control detects also possible inhibition of the PCR reaction. Amplification 
signals obtained from the samples are compared to a calibration curve, developed 
with the BKV Standards (Focus Diagnostics, California, USA), and quantified. This 
method has the lower limit of detection <510 copies/µL and >100 000 000 copies/µL 
higher detection limit.  
According to the protocol from the manufacturer, the reaction volume is 10 
µL including 4 µL mastermix, 1 µL primer-probe and 5µL BKV DNA. The 
amplification reaction conditions are described in Table 5.  
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Table 5 – Amplification Conditions 
Initial Cycle Time (s) 
Temperature 
(oC) 
Cycles 
Hold 120 97  
Denaturation 10 97 
40 
Annealing 30 60 
 
 
Figure 3 – Illustrative image of the 3M Integrated Cycler and the amplification disc. 
 
3. Variable definition 
For both studies the following variables were defined: heaematological diseases, 
status of disease, acute GVHD, overall survival, BKV infection, time to first positive result 
and duration of infection. Haematological diseases were classified into the following 
categories: (1) Acute leukemia (acute myeloid leukemia, acute lymphoid leukemia); (2) 
Chronic myeloproliferative disorders (chronic myeloid leukemia, polycythemia vera, 
mielofibrosis); (3) Chronic lymphoproliferative disorders (B-cell lymphoma, T-cell 
lymphoma, multiple myeloma, chronic lymphoid leukemia); (4) Myeolodisplasic syndrome 
(chronic myelomonocytic leukemia); (5) Aplastic anemia (Fanconi anemia, dyskeratosis 
congenital, Diamond-Blakfan syndrome); and, (6) other (metabolic disease, 
hemoglobinopathies). The status of disease at the time of allogeneic HSCT was classified 
as follows: (1) first complete remission or inactive disease after the first line of treatment; 
(2) second or following complete remission after equal or greater than second line 
treatment; and (3) relapse or active disease. Acute GVHD was defined as occurring during 
the 100 days after transplant, and chronic GVHD as occurring after 101 days from 
transplant. Overall survival was defined as the time between the day of allogeneic HSCT 
and the day of the last visit to hospital or the day of death. 
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BKV infection was defined as positive result by qPCR. Time to infection (TTI) 
was defined as the difference between the day of allogeneic HSCT and the day of 
first BKV positive result. Duration of infection (DOI) was defined as the difference 
between the day of first positive BKV result and the day of last positive BKV result.  
The last positive result was defined as the last positive detection.   
 
 
4. Statistical analysis 
Statistical analysis was performed with IBM® SPSS Statistics 20 software 
(Statistical Package for Social Sciences version 20.0) for Mac. Chi-square or 
Fisher’s exact test was used to compare the categorical variables with a 5% 
significance level. Univariate and multivariate logistic regression models were used 
to estimate odds ratio (OR) and the corresponding 95% confidence intervals (CI) as 
a measure of association between the categorical variables and the risk of BKV 
infection. Multivariate analyses were performed by logistic regression adjusting for 
covariates: gender, median age at allogeneic HSCT, stem cell source, phase at 
transplant, conditioning regimen, donor relation and, when applicable, to 
development of GVHD and BKV infection. Cox proportional models were used to 
assess the risk factors associated with BKV infection and death. The Kaplan-Meier 
method, adjusted by log-Rank and Breslow tests, was used to calculate the 
association between BKV infection and overall survival.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. RESULTS 
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1. Retrospective Study 
This study was conducted in order to determine the prevalence of BKV infection and 
characterize this infection and correlate with potential risk factors. 
 
1.1.Characteristics of the study population 
Clinical variables collected from patients are summarized in Table 6. In our study, 
the median age at allogeneic HSCT was 38 years (range:0-66) with 40 patients ≤20 years 
of age, 46 patients between 21 and 40 years of age, and 72 patients with >40 years.  
The majority of patients were underwent allogeneic HSCT for acute leukaemia 
(n=84, 53.2%) followed by chronic lymphoid diseases (n=26, 16.5%). Peripheral blood was 
the first choice for stem cell in 137 cases (86.7%) and relative donors were used in 82 cases 
(52.2%). One hundred and two patients (64.6%) underwent myeloablative conditioning 
regimen prior to transplantation and 101 were in first complete remission (69.2%) (Table 6).  
Table 6 – Baseline characteristics of the study population 
Variable n(%) 
Gender (n=158)  
      Female 65 (41.1) 
      Male 93 (58.9) 
Age (n=158)  
      ≤20 years old 40 (25.3) 
      21-40 years old 46 (29.1) 
      >40 years old 72 (45.6) 
Underlaying Diseases (n=158)  
      Acute Leukemias 84 (53.2) 
      Chronic Myeloproliferative Diseases 15 (9.5) 
      ChronicLymphoproliferative Diseases 26 (16.5) 
      Myelodisplastic/Myeloproliferative Diseases 17 (10.8) 
      Aplastic Anemia 10 (6.3) 
      Others 6 (3.8) 
Stem Cell Source (n=158)  
      Cord Blood 8 (5.1) 
      Bone Marrow 13 (8.2) 
      Peripheral Blood 137 (86.7) 
Phase at Transplantation (n=146)  
      Fisrt Complete Remission 101 (69.2) 
      Complete Remission 25 (17.1) 
      Active Disease 20 (13.7) 
Conditioning Regimen (n=158)  
      Reduced Intensity 56 (35.4) 
      Myeloablative 102 (64.6) 
Donor (n=157)  
      Related/Matched 82 (52.2) 
      Mismatched/Unrelated 
75 (47.8) 
1.2. BKV Infection 
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From the 158 patients submitted to allogeneic HSCT, 116 (73.4%) have 
developed BKV infection – Figure 4A. In our series, the median TTI was of 30 days 
(range: 2-302) and the median DOI was of 52 days (range: 4-484). The median viral 
load in the first positive result was 8.95 log copies/mL (range: 2.55-10.38) and the 
median viral load in last positive result was 7.92 log copies/mL (range: 2.22-9.61) – 
Figure 4B.  
 
Figure 4 – A: Percentage of BKV infection in patients submitted to allogeneic HSCT; B: Graphical 
representation of the median BKV viral load in the first and last positive result. 
 
Table 7 shows the detailed analysis of BKV infection and clinical variables. 
The statistical analysis revealed no significant differences on BKV infection 
prevalence according to gender, underlying disease, stem cell source, phase at 
transplantation and conditioning regimen. Nevertheless, results revealed that BKV 
infection was significantly less prevalent in patients with >38 years old (p=0.003; 
OR=0.33; 95%IC 0.15-0.69) and patients with mismatched or unrelated donors the 
infection is more prevalent (p=0.006; OR=2.87; 95%IC 1.34-6.18). The multivariate 
logistic regression analysis, combining all clinical variables revealed no significant 
associations for BKV infection with gender, age, stem cell source, phase at 
transplantation and conditioning regimen (p> 0.05), but mismatch or unrelated 
donors revealed a significant correlation with BKV infection (p=0.026). 
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Table 7 – Analysis of BKV infection among allogeneic HSCT recipients. 
Variable BKV 
n(%) 
P OR (95% CI) p* OR (95% IC)* 
Gender (n=158)      
Female (n=65) 46 (70.8) 
0.529 
1.26 
(0.62-2.56) 
0.263 
1.54 
(0.72-3.28) Male (n=93) 70 (75.3) 
Age (n=158)      
≤38 years old 67 (83.8) 
0.003 
0.33 
(0.15-0.69) 
0.118 
0.48 
(0.18-1.21) >38 years old 49 (62.8) 
Stem Cell Source (n=158)      
Peripheral Blood (n=137) 101 (73.7) 
0.825 
1.12 
(0.40-3.11) 
0.460 
1.58 
(0.47-5.34) Others (n=21) 15 (71.4) 
Phase at Transplantation (n=146)      
First Complete Remission (n=101) 75 (74.3) 
0.906 
0.95 
(0.43-2.12) 
0.915 
1.05 
(0.45-2.46) Complete Remission/Active (n=45) 33 (73.3) 
Conditioning Regimen (n=158)      
Reduced Intensity (n=56) 38 (67.9) 
0.241 
1.54 
(0.75-3.17) 
0.707 
1.18 
(0.50-2.78) Myeloablative (n=102) 78 (76.5) 
Donor (n=158)      
Matched/Related (n=82) 53 (64.6) 
0.006 
2.87 
(1.34-6.18) 
0.027 
2.66 
(1.12-6.32) Mismatched/Unrelated (n=75) 63 (84.0) 
p, Pearson Coeficient (ᵡ2-square test); OR, Odds Ratio; CI, Confidence Interval; * Multivariate 
Analysis. In bold are statistically significant results. 
 
 
1.3. Haemorrhagic Cystitis 
Of the 158 patients submitted allogeneic HSCT, 33 (20.9%) developed HC and 
these 30 (90.9%) developed BKV-associated HC (p=0.008, OR=4.59, 95%CI 1.32-15.95).  
Table 8 shows the detailed analysis of HC development and clinical variables. The 
statistical analysis revealed no significant differences on HC development according to 
gender, stem cell source, phase at transplantation, donor type and GVHD (p>0.05). 
Nevertheless, results revealed that patients undergoing myeloablative regimen conditioning 
have a high risk for HC development (p=0.022, OR=2.94, 95%CI 1.13-7.64). 
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Table 8 – Analysis of Haemorrhagic cystitis among allogeneic HSCT recipients 
Variable 
Haemorrhagic Cystitis 
n (%) 
P OR (95% CI) 
Gender (n=158)    
Female (n=65) 13 (20.0) 
0.792 1.11 (0.51-2.43) 
Male (n=92) 20 (21.7) 
Age (n=158)    
≤38 years old (n=79) 21 (26.6) 
0.085 0.50 (0.23-1.01) 
>38 years old (n=78) 12 (15.4) 
Stem Cell Source (n=158)    
Peripheral Blood (n=136) 27 (19.9) 
0.361 0.62 (0.22-1.75) 
Others (n=21) 6 (28.6) 
Phase at Transplantation (n=158)    
First Complete Remission (n=101) 23 (22.8) 
0.187 0.52 (0.20-1.39) 
Complete Remission/Active (n=45) 6 (13.3) 
Conditioning Regimen (n=158)    
Reduced Intensity (n=55) 6 (10.9) 
0.022 2.94 (1.13-7.64) 
Myeloablative (n=102) 27 (26.5) 
Donor (n=158)    
Matched/Related (n=82) 13 (15.9) 
0.088 1.97 (0.90-4.30) 
Mismatched/Unrelated (n=74) 20 (27.0) 
Acute GVHD (n=120)    
No (n=29) 2 (6.9) 
0.060 4.30 (0.95-19.57) 
Yes (n=91) 22 (24.2) 
GVHD <2 (n=24) 6 (25.0) 
0.966 1.24 (0.34-3.09) 
GVHD ≥2 (n=55) 14 (25.5) 
p, Pearson Coeficient (ᵡ2-square test); OR, Odds Ratio; CI, Confidence Interval            
 
1.4.Patient’s Outcome 
Regarding the success of engraftment, we observed that the rate of total 
engraftment success was 83.5% (132/158): 145 patients have obtained neutrophil 
count >1,0x109/µL while only 132 were able to obtain platelet count >2,0x1012/µL. 
Regarding BKV infection and engraftment, the study revealed that BKV infection 
was more common in patients with leucocyte recovery (74.5% vs 66.7%) and no 
difference was observed regarding platelet recovery (72.0% vs 74.2%) – Table 9. 
The median time to neutrophil engraftment was 15 days (range: 3-65) and to platelet 
engraftment was of 13 days (range; 8-377). The statistical analysis showed that 
there were no significant differences regarding the time to total engraftment and BKV 
status (p>0.05). 
Of all patients, 91 developed acute GVHD and from these, 55 had an acute 
GVHD ≥ grade 2 – Table 9. The analysis showed that BKV infection was significantly 
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more frequent in patients with acute GVHD (p=0.019; OR=2.86; 95%IC 1.16-7.05) but no 
difference was found regarding the grade of GVHD (p=0.422)  
We also observed that 104 patients developed CMV infection, from which 97 
developed early infection (<100 days) and the statistical analysis revealed that BKV 
coinfection with CMV was significantly more common (p=0.012; OR=2.51; 95%IC 1.22-
5.20) – Table 9. 
 
Table 9 – Analysis of patient outcome among allogeneic HSCT patients. 
Variable 
BKV Infection 
n(%) 
p OR (95% IC) 
Leucocyte Recovery    
 No 8 (66.7) 
0.385 1.46 (0.41-5.13) 
Yes 108 (74.5) 
Platelet Recovery    
 No 18 (72.0) 
0.815 1.12 (0.43-2.92) 
Yes 98 (74.2) 
CMV Infection (n=158)    
No (n=54) 33 (61.1) 
0.012 2.51 (1.22-5.20) 
Yes (n=104) 83 (79.8) 
Early (n=97) 78 (80.4) 
0.567 1.64 (0.30-9.12) 
Late (n=7) 5 (71.4) 
Acute GVHD (n=120)    
No (n=29) 17 (58.6) 
0.019 2.86 (1.16-7.05) 
Yes (n=91) 73 (80.2) 
Acute GVHD <2 (n=24) 21 (87.5) 
0.422 0.57 (0.14-2.27) 
Acute GVHD ≥2 (n=55) 44 (80.0) 
p, Pearson Coeficient (ᵡ2-square test); OR, Odds Ratio; CI, Confidence Interval. In bold are 
statistically significant results. 
 
The survival analysis of the follow-up of patients showed that 61 (38.6%) patients 
died and 97 (61.4%) are alive, and the median follow-up was of 19.0 months (range: 0-53). 
The mean overall survival of patients was 34.2±1.89 months, and we have observed that 
patients who develop BKV infection do not exhibit a significant reduction in overall survival 
(median: 33.3 vs 35.3 months; p=0.413; OR=1.36; 95%IC 0.65-2.86) – Figure 5.  
 
Figure 5 – Graphical representation of mean time of overall survival according to BKV infection. 
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2. Prospective Study 
We conducted this study in order to compare viral load in blood and urine samples 
and correlate viremia and viruria with HC development. 
 
2.1. Characteristics of the study population 
In our cohort, the median age at allogeneic HSCT was 40 years (range: 2-
65) and the majority of patients underwent transplant for acute leukaemias (n=13, 
61.9%). Peripheral blood was the first choice for stem cell in 19 cases (90.5%) and 
16 patients underwent reduced intensity conditioning regimen (76.2%). The 
description of clinical variables collected from patients is summarized in Table 10.  
 
Table 10 – Clinical variables of the study population 
Variable n(%) 
Gender (n=21)  
Female 11 (52.4) 
Male 10 (47.6) 
Underlaying Diseases (n=21)  
Acute Leukaemias 13 (61.9) 
Chronic Myeloproliferative Diseases 1 (4.8) 
Chronic Lymphoproliferative Diseases 2 (9.5) 
Myelodisplastic/Myeloproliferative Diseases 3 (14.3) 
Aplastic Anemia 1 (4.8) 
Others 1 (4.8) 
Stem Cell Source (n=21)  
Bone Marrow 2 (9.5) 
Peripheral Blood 19 (90.5) 
Conditioning Regimen (n=21)  
Reduced Intensity 16 (76.2) 
Myeloablative 5 (23.8) 
Donor (n=21)  
Related/Matched 14 (66.7) 
Mismatched/Unrelated 7(33.3) 
 
2.2.BKV Infection 
Of the 21 patients included in the study, we have been able to detect BKV in 
blood (viremia) in all patients with a median TTI of 76.0 days (range: 11-107), while 
for urine (viruria) we have detected only in 20 patients with median TTI of 79.0 days 
(range: 11-107). The median viral load at first positive result in blood was 2.75 log 
copies/mL (range: 2.71-3.95) and in urine was 5.03 log copies/mL (range: 2.71-8.00) 
(p<0.001) – Figure 6. 
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Figure 6 - Graphical representation of the median BKV viral load in urine and blood samples. 
 
Of the 21 patients we obtained 62 samples (31 blood and 31 urine samples) 
distributed according different times after HSCT: D+30 (n blood=6, n urine=6); D+60 (n blood=7, 
n urine=7); D+90 (n blood=14, n urine=14); D+120 (n blood=4, n urine=4). The median viral load at 
different times are shown in Table 11 and Figure 7.  Results show that overall, the viral load 
is higher in urine than in blood (p<0.001). 
Table 11 – Median viral load at different times after HSCT. 
Time 
Median 
P 
Urine Blood 
D+30 7.36 (4.87-8.00) 2.90 (2.71-4.11) 0.001 
D+60 5.64 (4.29-7.18) 2.71 (2.71-3.84) 0.003 
D+90 5.02 (2.71-8.00) 2.96 (2.71-4.31) 0.006 
D+120 6.54 (3.70-8.00) 3.47 (2.78-4.00) 0.077 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Graphical representation of the median viral load at different times after HSCT. 
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2.3.Patient Outcome 
During the follow-up, 13 (61.9%) patients developed acute GVHD, and 7 
(71.4%) patients had acute GVHD grade ≥2. Regarding the engraftment we 
observed that 13 (61.9%) patients have obtained leucocyte recovery while 12 
(57.1%) had platelet recovery – Table 12  
 
Table 12 – Characterization of acute GVHD, haematologic recovery and current status among 
allogeneic HSCT patients and median BKV viral load in urine and blood. 
 
Variable 
 Median (log copies/mL) 
n(%) Blood Urine 
Acute GVHD (n=21)    
No 7 (33.3) 2.71 (2.71-3.70) 5.98 (2.71-8.00) 
Yes 14 (66.7) 2.78 (2.71-3.95) 4.11 (2.71-8.00) 
Acute GVHD <2 4 (28.6) 2.71 (2.71-3.01) 3.69 (2.71-5.62) 
Acute GVHD ≥2 7 (71.4) 2.75 (2.71-3.84) 5.08 (3.40-7.36) 
Total Haematological Recovery (n=21)    
No 9 (42.9) 2.92 (2.71-3.70) 4.11 (3.40-8.00) 
Yes 12 (57.1) 2.71 (2.71-3.95) 5.62 (2.71-8.00) 
Leucocyte Recovery (n= 21)    
No 8 (38.1) 2.94 (2.71-3.70) 4.80 (3.40-8.00) 
Yes 13 (61.9) 2.71 (2.71-3.95) 5.10 (2.71-8.00) 
 
The global analysis of the follow-up of 21 patients showed that 5 (23.8%) 
patients died and 16 (76.2%) are alive. The overall survival of patients with viruria is 
63 days (range: 14-178) vs 71 days in patients without viruria. All patients developed 
viremia, and these patients have an overall survival of 64 days (range: 14-178). 
Patients who develop HC show an overall survival of 107 days while patients without 
this condition is 146 days.  
 
 
2.4. Correlation of BKV viral load with HC 
Of the 21 patients, three (14.3%) developed haematuria and consequently 
HC. Table 13 shows the characterization of patients that developed HC and the 
statistical analysis revealed no significant association with clinical variables (p> 
0.05). 
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Table 13 – Analysis of HC among patients submitted allogeneic HSCT. 
Variable 
Haemorrhagic Cystitis 
n(%) 
P OR (95%IC) 
Gender (n=21)    
Female (n=11) 1 (9.1) 
0.462 2.50 (0.19-32.80) 
Male (n=10) 2 (20.0) 
Age (n=21)    
<40 years old (n=10) 1 (10.0) 
0.538 2.00 (0.15-26.19) 
≥40 years old (n=11) 2 (18.2) 
Stem Cell Source (n=21)    
Bone Marrow (n=2) 1 (50.0) 
0.271 0.12 (0.01-2.70) 
Peripheral Blood (n=19) 2 (10.5) 
Conditioning Regimen (n=21)    
Reduced Intensity (n=16) 2 (12.5) 
0.579 1.75 (0.12-24.65) 
Myeloablative (n=5) 1 (20.0) 
Donor (n=21)    
Matched/Related (n=14) 2 (14.3) 
0.753 1.00 (0.07-13.37) 
Unmatched/Mismatched (n=7) 1 (14.3) 
Acute GVHD (n=21)    
No (n=7) 1 (14.3) 
0.726 1.00 (0.07-13.37) 
Yes (n=14) 2 (14.3) 
Acute GVHD <2 (n=4) 0 (0.0) 
0.328 1.40 (0.88-2.24) 
Acute GVHD ≥2 (n=7) 2 (28.6) 
Total Haematological Recovery (n=21)    
o (n=9) 1 (11.1) 
0.612 1.60 (0.12-20.99) 
Yes (n=12) 2 (16.7) 
Leucocyte Recovery (n=21)    
No (n=8) 1 (12.5) 
0.684 1.27 (0.10-16.81) 
Yes (n=13) 2 (15.4) 
Current Status (n=21)    
Alive (n=16) 2 (12.5) 
0.579 1.75 (0.12-24.64) 
Dead (n=5) 1 (20.0) 
p, Pearson Coeficient (ᵡ2-square test); OR, Odds Ratio; CI, Confidence Interval. In bold are 
statistically significant results. 
 
Regarding the development of haematuria and HC, we observed that there were 
differences regarding the viral load in urine. The result of the median viral load showed that 
patients with HC have a median value of 7.36 log copies/mL in urine and patients without 
HC have 4.11 log copies/mL – Table 14. 
 
Table 14 – Median viral load in blood and urine from patients with or without HC. 
Haemorrhagic Cystitis (n=21) n(%) 
Blood 
Median (range) 
Log copies/mL 
Urine 
Median (range) 
Log copies/mL 
No 18 (85.7) 2.85 (2.71-3.95) 4.11 (2.71-8.00) 
Yes 3 (14.3) 2.71 (2.71-2.75) 7.36 (6.20-8.00) 
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We have considering the median value of viral load in patients without HC as 
the cutoff point for clinical correlation. Table 15 shows the detailed analysis of BKV 
viruria (≥4.11 log copies/mL) and clinical variables. Univariate analysis showed no 
significant associations between BKV viruria and covariates (p>0.05), nevertheless, 
results point for a correlation regarding the conditioning regimen, since patients with 
myeloablative regimen seem to have higher viral load than reduced intensity 
regimen (p=0.055). 
Table 15 – Analysis of BKV viruria (≥4.11 log copies/mL) and clinical correlation. 
Variable 
BKV Viruria 
≥4.11 Log copies/mL 
n(%) 
p OR (95% IC) 
Gender (n=20)    
Female (n=11) 6 (54.5) 
0.670 1.67 (0.27-10.34) 
Male (n=9) 6 (66.7) 
Age (n=20)    
<40 years old (n=9) 5 (55.6) 
1.000 1.40 (0.23-8.47) 
≥40 years old (n=11) 7 (63.6) 
Stem Cell Source (n=20)    
Peripheral Blood (n=18) 10 (55.6) 
0.495 NC 
Bone Marrow (n=2) 2 (100) 
Conditioning Regimen (n=20)    
Reduced Intensity (n=15) 7 (46.7) 
0.055 NC 
Myeloablative (n=5) 5 (100) 
Donor (n=20)    
Matched/Related (n=13) 8 (61.5) 
1.000 0.83 (0.13-5.40) 
Mismatched/Unrelated (n=7) 4 (57.1) 
Acute GVHD (n=20)    
No (n=7) 5 (71.4) 
0.642 0.47 (0.07-3.34) 
Yes (n=13) 7 (53.8) 
Acute GVHD <2 (n=4) 1 (25.0) 
0.529 6.00 (0.35-101.6) 
Acute GVHD ≥2 (n=6) 4 (66.7) 
Haemorrhagic Cystitis (n=20)    
No (n=17) 9 (52.9) 
0.242 NC 
Yes (n=3) 3 (100) 
Total Haematological Recovery (n=20)    
No (n=9) 5 (55.6) 
1.000 1.40 (0.23-8.46) 
Yes (n=11) 7 (63.6) 
Leucocyte Haematological Recovery 
(n=20) 
   
No (n=8) 5 (62.5) 
1.000 0.84 (0.13-5.26) 
Yes (n=12) 7 (58.3) 
Current Status (n=20)    
Dead (n=4) 2 (50.0) 
1.000 0.60 (0.07-5.45) 
Alive (n=16) 10 (62.5) 
p, Pearson Coeficient (ᵡ2-square test); OR, Odds Ratio; CI, Confidence Interval; NC, not calculated.  
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BKV infects about 90% of the general population and clinical disease is seen in 
immunocompromised patients, including patients submitted to solid organ transplantation 
or HSCT [155, 169]. HC is one of the most frequent complications in allogeneic HSCT 
recipients, occurring in up to 25% of patients and is associated with significant morbidity 
and mortality [133, 155, 170]. There are several causes for the development of HC, 
nevertheless the infection by BKV is considered crucial, especially in immunocompromised 
hosts. [133]. 
Considering that BKV infection is a significant factor of morbidity and mortality in 
allogeneic HSCT patients, we performed a retrospective study to characterize this infection 
in our population.  
BKV infection affects 50-100% of patients submitted to allogeneic HSCT, and our 
study showed a prevalence of 73.4% [135, 171, 172]. The literature describes some risk 
factors for infection with BKV which were further analysed. Regarding to gender, male 
patients seem to have a high risk of infection by BKV what is justified in the literature by 
anatomical and physiological differences between men and women, predisposing men to 
higher frequency of infection [173]. Our retrospective study showed that BKV infection is 
more common in men (75.3% vs 70.8%). Another frequent risk factor for BKV infection is 
age, and literature suggests that BKV infection is more frequent in older patients, since the 
prevalence of infection tends to increase with increasing age [173]. However, our study 
showed that BKV infection is more common in patients with ≤38 years old (83.8% vs 62.8%, 
p=0.003, OR=0.33, 95%CI=0.15-0.69). These results may be biased, since our population 
is young. The source of cells is another of the risk factors associated with infection by BKV 
and umbilical cord blood and peripheral blood receivers are described as having a higher 
frequency of infection BKV, since it is reported that these patients have a haematological 
recovery slower making the patient more susceptible to replication of BKV [149]. However, 
our results showed no significant differences regarding the source , nevertheless our results 
may, again, be biased, since most patients in this study received stem cells from peripheral 
blood. The conditioning regime also shows to be an important risk factor in particular 
myeloablative conditioning, since in patients receptors of this type of conditioning the 
immunosuppression condition is high, thus allowing reactivation and viral replication [171]. 
Our results, revealed an increased tendency for BKV association with myeloablative 
contioning regimen. in literature, mismatched/unrelated donor receptors are described as 
having a higher prevalence of infection, since the mismatch can restrict the antiviral immune 
response, and this mismatch can contribute to a favourable environment for replication and 
reactivation of BKV [171]. Our results are in agreement with that described in the literature, 
with a higher prevalence in these cases (84.0% vs 64.6%, p=0.027, OR=2.66, 95%CI=1.12-
6.32). Our retrospective study also revealed that 79.8% of patients have co-infection with  
  
CMV, which is in agreement with literature suggesting that this association should 
be further analysed for possible interactions and prediction of viral reactivation [177]. 
It is known that patients submitted to allogeneic HSCT may suffer reactivation of 
BKV and consequently develop BKV-associated HC [174]. HC is characterized by episodes 
of haematuria and urinary tract obstruction and is associated with significant morbidity [146]. 
However, BKV infection alone is not sufficient for inducing HC, and additional factors are 
necessary to predict patients at risk for HC, as: presence of pre-transplant IgG antibody 
titter, conditioning regimen, donor type and acute GVHD [146]. The literature suggests that 
in case of the donor and recipient are seropositive for IgG anti-BKV there is greater risk of 
developing infection BKV and consequently develop HC [176]. However, in this work we did 
not analyze this risk factor, since, by it is not performed routinely in these patients. A recent 
study showed that HC development is significantly more common in patients undergoing 
myeloablative conditioning regimen, which we corroborate in our study (26.5% vs 10.9%, 
p=0.022, OR=2.94, 95%CI=1.13-7.64). It is suggested that these individuals have high 
immunosuppression, and when the reconstitution of the immune system occurs it will lead 
to a strong immune response against BKV present in uroepithelial cells, causing damage in 
these cells and subsequently the development of HC [176]. Our retrospective study also 
showed that mismatched/unrelated donors receivers have a higher incidence of HC (27.0% 
vs 15.9%). The literature suggests that in these cases alloimmune responses from donor 
lymphocytes result in donor lymphocytes targeting target the recipient uroepithelial cells 
and causing epithelial damage [147]. We have also observed that  patients who developed 
acute GVHD during follow-up have a higher incidence of HC (24.2% vs 6.9%). The literature 
suggests that in these cases, acute GVHD functions as a cofactor for the development of 
HC, and even suggested that cystitis is a form of GVHD. Once again, the alloimmune 
reactions are responsible for damage to uroepithelial cells, predisposing to HC 
development. 
There are several methods used for BKV detection and subsequent diagnosis and 
also different samples are being discussed [149, 181-186]. Indeed, the sample that most 
frequently used to detect BKV is urine, but in recent years many studies have been 
performed using whole blood [149, 181]. Hence, we have decided to develop a prospective 
study including blood and urine samples in order to determine which is the best sample to 
be used for early detection of BKV-associate HC. Regarding the method for detection, 
despite some authors use PCR, nested-PCR, ELISA and cytology quantitative Real-Time 
PCR has becoming the gold standard method for BKV detection [182-185][186]. 
Furthermore, there have been another issues considered in BKV monitoring in 
immunocompromised host, such as the time and frequency of monitorization [153, 187]. 
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Since there are no specific timings for monitoring BKV infection, we performed a 
prospective study comparing samples obtained at 30th, 60th, 90th and 120th days after 
transplant. With these samples we compared the median viral loads in blood and urine 
samples and found that the viral load in urine is higher than in blood. A previous study 
compared urine and blood samples of 124 patients undergoing allogeneic HSCT but did not 
established timings, since the sample collection were performed depending on how often 
patients were seen in health care [187]. However, other study had used the same type of 
samples but its collection was performed weekly between the day of transplant (D+0) and 
D+50 [153].  
Correlating the presence of HC and viral load, our prospective study revealed that 
median viral load in urine in patients with HC was 7.36 log copies/mL whereas in patients 
without HC was only 4.11 log copies/mL. However, these differences were not observed in 
blood viral load. Thus, the value of 4.11 log copies/mL was used as cut-off to correlate with 
the development of HC. Is suggested in the literature that an increase in viral load in urine 
of 3 log copies/mL is a risk factor for the development of HC. However, when we correlate 
our viruria value with the clinicopathological variables we observed no significant 
differences.  
The major limitation that the prospective study presented were the small population 
that was included and the fact that we could not get the same number of blood and urine 
samples within the stipulated time.To improve the prospective study, we expect to increase 
the population, ensure the same number of samples within the stipulated period, increase 
the time of follow-up and include a control group in order to see differences in viral load and 
kinetic infection. Regarding the type of samples, we could continue to use blood and urine, 
and perhaps include plasma samples. 
With these studies we found that there is a lack of guidelines for BKV monitorization 
in allogeneic HSCT patients. Here we propose an algorithm based on the follow-up of 
patients submitted to kidney transplant for prevention of nephritis, HC and kidney failure: 
screening all allogeneic HSCT patients for BKV, with quantitative Real-Time PCR, in urine 
and blood samples at least bimonthly for the first 3-6 months after transplantation, then 
every months until the end of the first year after transplantation; and also, whenever there 
is an unexplained rise in serum creatinine, which is associated with kidney damage [190]. 
Thus, we suggest that it would be important to test this model in order to verify if it would be 
beneficial for the early detection of patients at risk for HC. It would be interesting test this 
model with plasma samples instead whole blood since viremia results are not very 
conclusive. 
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The BKV infection is one of the most important comorbidities in allogeneic HSCT 
patients, since this virus is a risk factor for development of HC. Our retrospective study 
showed a prevalence of infection of 73.4%. This study allows characterize the studied 
population and found as risk factors for infection by BKV and subsequent development of 
HC: male gender, advanced age, myeloablative conditioning, mismatched/unrelated 
donors, stem cell source, co-infection with CMV and the development of acute GVHD. 
Correlating the presence of HC and viral load, our prospective study also revealed 
that median viral load in urine in patients with HC was 7.36 log copies/mL whereas in 
patients without HC was only 4.11 log copies/mL. So we found that patients with viruria 
≥4.11 log copies/mL are associated with increased risk of HC development. 
These results reinforce the importance of developing guidelines for BKV detection 
and HC prediction and early-diagnosis in allogeneic HSCT recipients, especially by 
identifying those at higher risk. 
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